CD22 clone 4KB128

Working With CRT

Licensing Opportunities

Small Molecules

Biological Therapeutics

Enabling Technology

Antibody Catalogue

Privileged Access Section

CRT's Development Pipeline

Commercialisation Routes

Anti-CD22 Antibody Profile

Antigen:	CD22 (BL-CAM)
Relevance:	CD22 is first expressed in the cytomplasm of pre- and pro- B cells. CD22 is broadly expressed in normal and neoplastic B cells and absent from other leucocytes and tissues. CD22 is a member of the immunoglobulin superfamily and serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. It also associates with tyrosine kinases and play a role in signal transduction and B-cell activation. CD22 is strongly expressed in hairy cell leukaemias
Clone:	4KB128
Subclass:	IgG1, kappa
Applications:	Immunohistochemistry (frozen sections), FACS
Immunogen:	B cell lymphoma cells
Reactivity:	Human
Species raised in:	Mouse
Fusion partner:	NS-1
Recommended growth conditions:	RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT
References:	Campana D, Janossy G, Bofill M, Trejdosiewicz LK, Ma D, Hoffbrand AV, Mason DY, Lebacq AM, Forster HK (1985) Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol 134:1524-1530. Mason DY, Stein H, Gerdes J, Pulford KAF, Ralfkiaer E, Falini B, Erber WN, Micklem K, Gatter KC (1987) Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 69:836-840. Law CL, Sidorenko SP, Clark EA (1994) Regulation of lymphocyte activation by the cell-surface molecule CD22. Immunol Today 15:442-449
Notes:	Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well

For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com

Click here to view Notes and Disclaimer information

[back]